Share Price and Basic Stock Data
Last Updated: March 12, 2025, 9:27 am
PEG Ratio | 0.00 |
---|
Competitors of Asarfi Hospital Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Asarfi Hospital Ltd | 180 Cr. | 91.4 | 112/52.8 | 35.8 | 0.00 % | 11.4 % | 7.50 % | 10.0 | |
Industry Average | 180.00 Cr | 91.40 | 0 | 35.80 | 0.00% | 11.40% | 7.50% | 10.00 |
Quarterly Result
Metric | Dec 2023 | Dec 2024 |
---|---|---|
Sales | 20.05 | 32.89 |
Expenses | 16.04 | 25.90 |
Operating Profit | 4.01 | 6.99 |
OPM % | 20.00% | 21.25% |
Other Income | 1.20 | 0.89 |
Interest | 0.60 | 1.18 |
Depreciation | 3.25 | 3.04 |
Profit before tax | 1.36 | 3.66 |
Tax % | 102.94% | 25.41% |
Net Profit | -0.05 | 2.72 |
EPS in Rs | -0.03 | 1.38 |
Last Updated: February 28, 2025, 3:25 pm
Below is a detailed analysis of the quarterly data for Asarfi Hospital Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹32.89 Cr.. The value appears strong and on an upward trend. It has increased from 20.05 Cr. (Dec 2023) to ₹32.89 Cr., marking an increase of ₹12.84 Cr..
- For Expenses, as of Dec 2024, the value is ₹25.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.04 Cr. (Dec 2023) to ₹25.90 Cr., marking an increase of ₹9.86 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹6.99 Cr.. The value appears strong and on an upward trend. It has increased from 4.01 Cr. (Dec 2023) to ₹6.99 Cr., marking an increase of ₹2.98 Cr..
- For OPM %, as of Dec 2024, the value is 21.25%. The value appears strong and on an upward trend. It has increased from 20.00% (Dec 2023) to 21.25%, marking an increase of 1.25%.
- For Other Income, as of Dec 2024, the value is ₹0.89 Cr.. The value appears to be declining and may need further review. It has decreased from 1.20 Cr. (Dec 2023) to ₹0.89 Cr., marking a decrease of 0.31 Cr..
- For Interest, as of Dec 2024, the value is ₹1.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.60 Cr. (Dec 2023) to ₹1.18 Cr., marking an increase of ₹0.58 Cr..
- For Depreciation, as of Dec 2024, the value is ₹3.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.25 Cr. (Dec 2023) to ₹3.04 Cr., marking a decrease of 0.21 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹3.66 Cr.. The value appears strong and on an upward trend. It has increased from 1.36 Cr. (Dec 2023) to ₹3.66 Cr., marking an increase of ₹2.30 Cr..
- For Tax %, as of Dec 2024, the value is 25.41%. The value appears to be improving (decreasing) as expected. It has decreased from 102.94% (Dec 2023) to 25.41%, marking a decrease of 77.53%.
- For Net Profit, as of Dec 2024, the value is ₹2.72 Cr.. The value appears strong and on an upward trend. It has increased from -0.05 Cr. (Dec 2023) to ₹2.72 Cr., marking an increase of ₹2.77 Cr..
- For EPS in Rs, as of Dec 2024, the value is 1.38. The value appears strong and on an upward trend. It has increased from ₹-0.03 (Dec 2023) to 1.38, marking an increase of ₹1.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: September 23, 2024, 3:00 pm
Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|
Sales | 42.87 | 54.12 | 65.19 | 68.81 | 80.93 |
Expenses | 36.63 | 46.08 | 54.41 | 55.04 | 64.61 |
Operating Profit | 6.24 | 8.04 | 10.78 | 13.77 | 16.32 |
OPM % | 14.56% | 14.86% | 16.54% | 20.01% | 20.17% |
Other Income | 0.29 | 0.28 | 0.98 | 2.33 | 1.67 |
Interest | 0.53 | 0.63 | 0.70 | 1.34 | 2.92 |
Depreciation | 2.42 | 2.91 | 3.35 | 3.87 | 8.78 |
Profit before tax | 3.58 | 4.78 | 7.71 | 10.89 | 6.29 |
Tax % | 26.54% | 25.94% | 25.81% | 26.35% | 33.07% |
Net Profit | 2.63 | 3.53 | 5.73 | 8.02 | 4.21 |
EPS in Rs | 21.48 | 28.83 | 46.79 | 5.53 | 2.14 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|
YoY Net Profit Growth (%) | 34.22% | 62.32% | 39.97% | -47.51% |
Change in YoY Net Profit Growth (%) | 0.00% | 28.10% | -22.36% | -87.47% |
Asarfi Hospital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 14% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 6% |
TTM: | -47% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 17% |
Last Year: | 8% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 14, 2024, 5:50 pm
Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|
Equity Capital | 1.25 | 1.25 | 1.25 | 14.50 | 19.68 | 19.68 |
Reserves | 12.12 | 15.65 | 21.38 | 27.36 | 50.78 | 55.02 |
Borrowings | 5.44 | 7.13 | 11.63 | 17.20 | 31.91 | 43.92 |
Other Liabilities | 8.83 | 13.26 | 28.45 | 34.36 | 51.70 | 39.69 |
Total Liabilities | 27.64 | 37.29 | 62.71 | 93.42 | 154.07 | 158.31 |
Fixed Assets | 18.40 | 22.42 | 30.87 | 38.57 | 93.71 | 89.26 |
CWIP | 0.19 | 1.62 | 9.34 | 17.91 | 0.00 | 0.58 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Other Assets | 9.05 | 13.25 | 22.50 | 36.94 | 60.35 | 68.46 |
Total Assets | 27.64 | 37.29 | 62.71 | 93.42 | 154.07 | 158.31 |
Below is a detailed analysis of the balance sheet data for Asarfi Hospital Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹19.68 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹19.68 Cr..
- For Reserves, as of Sep 2024, the value is ₹55.02 Cr.. The value appears strong and on an upward trend. It has increased from ₹50.78 Cr. (Mar 2024) to ₹55.02 Cr., marking an increase of 4.24 Cr..
- For Borrowings, as of Sep 2024, the value is ₹43.92 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹31.91 Cr. (Mar 2024) to ₹43.92 Cr., marking an increase of 12.01 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹39.69 Cr.. The value appears to be improving (decreasing). It has decreased from ₹51.70 Cr. (Mar 2024) to ₹39.69 Cr., marking a decrease of 12.01 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹158.31 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹154.07 Cr. (Mar 2024) to ₹158.31 Cr., marking an increase of 4.24 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹89.26 Cr.. The value appears to be declining and may need further review. It has decreased from ₹93.71 Cr. (Mar 2024) to ₹89.26 Cr., marking a decrease of 4.45 Cr..
- For CWIP, as of Sep 2024, the value is ₹0.58 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.00 Cr. (Mar 2024) to ₹0.58 Cr., marking an increase of 0.58 Cr..
- For Investments, as of Sep 2024, the value is ₹0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.01 Cr..
- For Other Assets, as of Sep 2024, the value is ₹68.46 Cr.. The value appears strong and on an upward trend. It has increased from ₹60.35 Cr. (Mar 2024) to ₹68.46 Cr., marking an increase of 8.11 Cr..
- For Total Assets, as of Sep 2024, the value is ₹158.31 Cr.. The value appears strong and on an upward trend. It has increased from ₹154.07 Cr. (Mar 2024) to ₹158.31 Cr., marking an increase of 4.24 Cr..
Notably, the Reserves (₹55.02 Cr.) exceed the Borrowings (43.92 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|
Free Cash Flow | 0.80 | 0.91 | -0.85 | -3.43 | -15.59 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|
Debtor Days | 20.01 | 14.16 | 29.84 | 89.80 | 109.41 |
Inventory Days | 23.12 | 13.20 | 15.50 | 25.89 | 32.33 |
Days Payable | 155.80 | 22.69 | 34.13 | 90.98 | 445.29 |
Cash Conversion Cycle | -112.67 | 4.67 | 11.22 | 24.72 | -303.55 |
Working Capital Days | 18.05 | -7.15 | -4.20 | 51.56 | -3.02 |
ROCE % | 25.26% | 28.86% | 26.19% | 11.41% |
This stock is not held by any mutual fund
Key Financial Ratios
Month | Mar 24 |
---|---|
FaceValue | 10.00 |
Basic EPS (Rs.) | 2.31 |
Diluted EPS (Rs.) | 2.31 |
Cash EPS (Rs.) | 6.58 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 35.78 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 35.78 |
Revenue From Operations / Share (Rs.) | 42.89 |
PBDIT / Share (Rs.) | 9.01 |
PBIT / Share (Rs.) | 4.54 |
PBT / Share (Rs.) | 3.17 |
Net Profit / Share (Rs.) | 2.11 |
NP After MI And SOA / Share (Rs.) | 2.11 |
PBDIT Margin (%) | 20.99 |
PBIT Margin (%) | 10.58 |
PBT Margin (%) | 7.39 |
Net Profit Margin (%) | 4.93 |
NP After MI And SOA Margin (%) | 4.93 |
Return on Networth / Equity (%) | 5.91 |
Return on Capital Employeed (%) | 7.93 |
Return On Assets (%) | 2.70 |
Long Term Debt / Equity (X) | 0.28 |
Total Debt / Equity (X) | 0.45 |
Current Ratio (X) | 1.13 |
Quick Ratio (X) | 1.08 |
Interest Coverage Ratio (X) | 6.58 |
Interest Coverage Ratio (Post Tax) (X) | 2.55 |
Enterprise Value (Cr.) | 142.87 |
EV / Net Operating Revenue (X) | 1.69 |
EV / EBITDA (X) | 8.06 |
MarketCap / Net Operating Revenue (X) | 1.52 |
Price / BV (X) | 1.83 |
Price / Net Operating Revenue (X) | 1.52 |
EarningsYield | 0.03 |
After reviewing the key financial ratios for Asarfi Hospital Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 24, the value is 2.31. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 24, the value is 2.31. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 24, the value is 6.58. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 35.78. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 35.78. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 42.89. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 9.01. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 24, the value is 4.54. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 24, the value is 3.17. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 2.11. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 2.11. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 24, the value is 20.99. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 24, the value is 10.58. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 24, the value is 7.39. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 24, the value is 4.93. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 4.93. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 24, the value is 5.91. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 24, the value is 7.93. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 24, the value is 2.70. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.28. This value is within the healthy range. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.45. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 24, the value is 1.13. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 24, the value is 1.08. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 6.58. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.55. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 24, the value is 142.87. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.69. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 24, the value is 8.06. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 24, the value is 1.83. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
- For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Asarfi Hospital Ltd:
- Net Profit Margin: 4.93%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.93% (Industry Average ROCE: 11.4%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.91% (Industry Average ROE: 7.5%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 0)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.45
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.93%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Hospitals & Medical Services | 4th Floor, Asarfi Hospital, Baramuri, B Polytechnic, Dhanbad Jharkand 828130 | cs@asarfihospital.com http://www.asarfi.in |
Management | |
---|---|
Name | Position Held |
Mr. Udai Pratap Singh | Managing Director |
Mrs. Madhuri Singh | Executive Director |
Mr. Gopal Singh | Executive Director |
Dr. Sukanti Kumar Das | Non Executive Director |
Mrs. Rajkumari Sharma | Independent Director |
Mr. Amit Kumar Barnwal | Independent Director |
FAQ
What is the latest intrinsic value of Asarfi Hospital Ltd?
The latest intrinsic value of Asarfi Hospital Ltd as on 12 March 2025 is ₹32.86, which is 64.05% lower than the current market price of 91.40, indicating the stock is overvalued by 64.05%. The intrinsic value of Asarfi Hospital Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹180 Cr. and recorded a high/low of ₹112/52.8 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹55.02 Cr and total liabilities of ₹158.31 Cr.
What is the Market Cap of Asarfi Hospital Ltd?
The Market Cap of Asarfi Hospital Ltd is 180 Cr..
What is the current Stock Price of Asarfi Hospital Ltd as on 12 March 2025?
The current stock price of Asarfi Hospital Ltd as on 12 March 2025 is ₹91.4.
What is the High / Low of Asarfi Hospital Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Asarfi Hospital Ltd stocks is ₹112/52.8.
What is the Stock P/E of Asarfi Hospital Ltd?
The Stock P/E of Asarfi Hospital Ltd is .
What is the Book Value of Asarfi Hospital Ltd?
The Book Value of Asarfi Hospital Ltd is 35.8.
What is the Dividend Yield of Asarfi Hospital Ltd?
The Dividend Yield of Asarfi Hospital Ltd is 0.00 %.
What is the ROCE of Asarfi Hospital Ltd?
The ROCE of Asarfi Hospital Ltd is 11.4 %.
What is the ROE of Asarfi Hospital Ltd?
The ROE of Asarfi Hospital Ltd is 7.50 %.
What is the Face Value of Asarfi Hospital Ltd?
The Face Value of Asarfi Hospital Ltd is 10.0.